Genzyme A/S

Genzyme was founded in 1981 in Boston, and is one of the world’s leading biotechnology companies. Genzyme has pioneered the development and delivery of transformative therapies for 30 years, for patients affected by rare and debilitating.


We accomplish our goals through world-class research, collaboration with the global and local patient community, and with the compassion and commitment of our employees. With a focus on rare diseases and multiple sclerosis, we at Genzyme are dedicated to making a positive impact on the lives of the patients and families we serve. Genzyme’s portfolio, which is marketed in countries around the world, represent groundbreaking and life-saving advances in medicine.

Genzyme a Sanofi company
Genzyme has since 2011 been a part of the Sanofi Group. As a sanofi company, Genzyme benefits from the reach and resources of one of the world’s largest pharmaceutical companies, with a shared commitment to improving the lives of patients.

Genzyme – a rare disease company
Genzyme has products and development programs that use a diversity of protein product platforms for rare diseases. Each protein is unique and requires extensive research, sophisticated knowledge and meticulous execution of complex techniques in genetics, molecular biology, biochemistry, and cell culture in order to transform the protein into a product that could improve patients’ lives.

For more than two decades, partnering with universities, hospitals, research institutions and private companies has been a fundamental part of the business in order to develop new treatments for rare diseases.

We at Genzyme seek to combine our strengths with those of others and to work collaboratively with partners to develop and commercialize therapeutic products that improve the lives of patients. To this end, we search globally for innovative product candidates at various development stages, with a clear goal to accelerate the delivery of novel and highly effective products and services to the global marketplace.

Genzyme – a MS company
In our struggle to produce medicine for unmet needs, we are currently researching for drugs against Multiple Sclerosis. No cure exists for MS. Currently available therapies do not stop, let alone reverse, disability progression, and are associated with various adverse events. The prevalence of MS is increasing, imparting high morbidity among a young population. We want to help these patients, and are strongly engaged in research for drugs that may improve their lives.

Genzyme – a patient-focused company
At Genzyme we are driven by our desire to make a major positive impact on the lives of patients. Because we focus our efforts primarily on rare and life-threatening illnesses, we feel a special bond to our patients, and they serve as a constant source of inspiration for us.

Improving the lives of patients is and always will be our top priority. We exist to innovate on behalf of people with debilitating diseases. By seeking out unmet medical needs and developing solutions, we provide hope to patients who otherwise would have no treatment options. This patient focus pervades everything we do.

Genzyme A/S
+45 32 71 26 00
+45 32 71 26 01